Pregnancy outcomes after maternal exposure to topical corticosteroids: A UK population-based cohort study

JAMA Dermatology

Volumn 149, Issue 11, 2013, Pages 1274-1280

  Chi, Ching Chi ^a   Wang, Shu Hui ^b   Mayon White, Richard ^c   Wojnarowska, Fenella ^d  

^a CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^b ORIENTAL INSTITUTE OF TECHNOLOGY   (Taiwan)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID;

ADOLESCENT; ADULT; APGAR SCORE; ARTICLE; CESAREAN SECTION; CLEFT LIP FACE PALATE; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; DRUG POTENCY; FEMALE; FETUS DEATH; HUMAN; LOW BIRTH WEIGHT; MAJOR CLINICAL STUDY; NATIONAL HEALTH SERVICE; PERINATAL DRUG EXPOSURE; POPULATION RESEARCH; PREGNANCY OUTCOME; PREMATURE LABOR; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; SKIN DISEASE; UNITED KINGDOM; VAGINAL DELIVERY;

ABNORMALITIES, DRUG-INDUCED; ADMINISTRATION, TOPICAL; APGAR SCORE; BIRTH WEIGHT; COHORT STUDIES; DERMATOLOGIC AGENTS; FEMALE; GLUCOCORTICOIDS; GREAT BRITAIN; HUMANS; INFANT, LOW BIRTH WEIGHT; INFANT, NEWBORN; MATERNAL EXPOSURE; PREGNANCY; PREGNANCY COMPLICATIONS; PREGNANCY OUTCOME; RETROSPECTIVE STUDIES; SKIN CREAM; SKIN DISEASES;

EID: 84888621561     PISSN: 21686068     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamadermatol.2013.5768     Document Type: Article

References (29)

1. Chi CC. Evidence-Based Assessment of the Safety of Topical Corticosteroids in Pregnancy [thesis]. Oxford, England: Nuffield Department of Clinical Medicine, University of Oxford; 2009.
2. Diflorasone diacetate cream [package insert]. Hawthorne, NY: Taro Pharmaceuticals; 1999.
3. Narama I. Reproduction studies of diflorasone diacetate (DDA). IV. teratogenicity study in rabbits by percutaneous administration. Pharmacometrics. 1984;28(2):241-250.
4. Mehta DK, ed. British National Formulary. 53rd ed. London, England: BMJ Publishing Group Ltd and RPS Publishing; 2007.
5. Briggs GG, Freeman RK, Yaffe SJ. Drugs in Pregnancy and Lactation. 8th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2008.
6. Chi CC, Wang SH, Kirtschig G, Wojnarowska F. Systematic review of the safety of topical corticosteroids in pregnancy. J Am Acad Dermatol. 2010;62(4):694-705.
7. Chi CC, Lee CW, Wojnarowska F, Kirtschig G. Safety of topical corticosteroids in pregnancy. Cochrane Database Syst Rev. 2009;(3):CD007346.
8. Källén B. Maternal drug use and infant cleft lip/palate with special reference to corticoids. Cleft Palate Craniofac J. 2003;40(6):624-628.
9. Pradat P, Robert-Gnansia E, Di Tanna GL, Rosano A, Lisi A, Mastroiacovo P; Contributors to the MADRE database. First trimester exposure to corticosteroids and oral clefts. Birth Defects Res A Clin Mol Teratol. 2003;67(12):968-970.
10. Carmichael SL, Shaw GM, Ma C, Werler MM, Rasmussen SA, Lammer EJ; National Birth Defects Prevention Study. Maternal corticosteroid use and orofacial clefts. Am J Obstet Gynecol. 2007;197(6):e1-e7; 683-684.
11. Edwards MJ, Agho K, Attia J, et al. Case-control study of cleft lip or palate after maternal use of topical corticosteroids during pregnancy. Am J Med Genet A. 2003;120A(4):459-463.
12. Hviid A, Mølgaard-Nielsen D. Corticosteroid use during pregnancy and risk of orofacial clefts. CMAJ. 2011;183(7):796-804.
13. Czeizel AE, Rockenbauer M. Population-based case-control study of teratogenic potential of corticosteroids. Teratology. 1997;56(5):335-340.
14. Chi CC, Mayon-White RT, Wojnarowska FT. Safety of topical corticosteroids in pregnancy: a population-based cohort study. J Invest Dermatol. 2011;131(4):884-891.
15. Mahé A, Perret JL, Ly F, Fall F, Rault JP, Dumont A. The cosmetic use of skin-lightening products during pregnancy in Dakar, Senegal: a common and potentially hazardous practice. Trans R Soc Trop Med Hyg. 2007;101(2):183-187.
16. Mygind H, Thulstrup AM, Pedersen L, Larsen H. Risk of intrauterine growth retardation, malformations and other birth outcomes in children after topical use of corticosteroid in pregnancy. Acta Obstet Gynecol Scand. 2002;81(3):234-239.
17. Stergachis A, Saunders KW, Davis RL, et al. Examples of automated databases. In: Strom BL, Kimmel SE, eds. Textbook of Pharmacoepidemiology. Chichester, England: John Wiley & Sons, Ltd; 2006:198-204.
18. Casey BM, McIntire DD, Leveno KJ. The continuing value of the Apgar score for the assessment of newborn infants. N Engl J Med. 2001;344(7):467-471.
19. Chung KC, Kowalski CP, Kim HM, Buchman SR. Maternal cigarette smoking during pregnancy and the risk of having a child with cleft lip/palate. Plast Reconstr Surg. 2000;105(2):485-491.
20. Spilson SV, Kim HJ, Chung KC. Association between maternal diabetes mellitus and newborn oral cleft. Ann Plast Surg. 2001;47(5):477-481.
21. Brodsky D, Christou H. Current concepts in intrauterine growth restriction. J Intensive Care Med. 2004;19(6):307-319.
22. Steer P. The epidemiology of preterm labour. BJOG. 2005;112(suppl 1):1-3.
23. Smith GC. Predicting antepartum stillbirth. Curr Opin Obstet Gynecol. 2006;18(6):625-630.
24. Arosarena OA. Cleft lip and palate. Otolaryngol Clin North Am. 2007;40(1):27-60; vi.
25. Wyszynski DF, Duffy DL, Beaty TH. Maternal cigarette smoking and oral clefts: a meta-analysis. Cleft Palate Craniofac J. 1997;34(3):206-210.
26. Seeger JD, Lanza LL, West WA, Fernandez C, Rivero E. Pregnancy and pregnancy outcome among women with inflammatory skin diseases. Dermatology. 2007;214(1):32-39.
27. Yang YW, Chen CS, Chen YH, Lin HC. Psoriasis and pregnancy outcomes: a nationwide population-based study. J Am Acad Dermatol. 2011;64(1):71-77.
28. Chi CC, Wang SH, Charles-Holmes R, et al. Pemphigoid gestationis: early onset and blister formation are associated with adverse pregnancy outcomes. Br J Dermatol. 2009;160(6):1222-1228.
29. Chi CC, Kirtschig G, Aberer W, et al. Evidence-based (S3) guideline on topical corticosteroids in pregnancy. Br J Dermatol. 2011;165(5):943-952.